Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides by Heuts, J.M.M. et al.
RESEARCH PAPER
Cationic Liposomes: A Flexible Vaccine Delivery System
for Physicochemically Diverse Antigenic Peptides
Jeroen Heuts 1,2 & Eleni Maria Varypataki 2 & Koen van der Maaden 2 & Stefan Romeijn 2 &
Jan Wouter Drijfhout1 & Anton Terwisscha van Scheltinga3 & Ferry Ossendorp1 & Wim Jiskoot2
Received: 15 June 2018 /Accepted: 3 September 2018
# The Author(s) 2018
ABSTRACT
Purpose Personalized peptide-based cancer vaccines will be
composed of multiple patient specific synthetic long peptides
(SLPs) which may have various physicochemical properties.
To formulate such SLPs, a flexible vaccine delivery system is
required. We studied whether cationic liposomes are suitable
for this purpose.
Methods Fifteen SIINFEKL T cell epitope-containing SLPs,
widely differing in hydrophobicity and isoelectric point, were
separately loaded in cationic liposomes via the dehydration-
rehydration method. Particle size and polydispersity index
(PDI) were measured via dynamic light scattering (DLS),
and zeta potential with laser Doppler electrophoresis.
Peptide loading was fluorescently determined and the immu-
nogenicity of the formulated peptides was assessed in co-
cultures of dendritic cells (DCs) and CD8+ T-cells in vitro.
Results All SLPs were loaded in cationic liposomes by using
three different loading method variants, depending on the
SLP characteristics. The fifteen liposomal formulations had
a comparable size (< 200 nm), PDI (< 0.3) and zeta potential
(22–30 mV). Cationic liposomes efficiently delivered the SLPs
to DCs that subsequently activated SIINFEKL-specific CD8+
T-cells, indicating improved immunological activity of the
SLPs.
Conclusion Cationic liposomes can accommodate a wide
range of different SLPs and are therefore a potential delivery
platform for personalized cancer vaccines.
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INTRODUCTION
Therapeutic cancer vaccines aim to amplify a specific cellular
immune response directed towards the patients’ own tumor
(1,2). T-cells are able to identify and destroy malignant cells
through the recognition of tumor specific antigens.
Vaccination with synthetic long peptides (SLPs) containing a
cytotoxic (CD8+) as well as a helper (CD4+) T cell epitope has
shown to induce tumor specific T cell responses that were able
to control or even regress tumor outgrowth (1–7). In order to
provoke such functional immune responses, the SLPs have to
be delivered to and taken up by dendritic cells (DCs), and be
processed and presented on MHC molecules to activate
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tumor specific T cells. However, SLPs by themselves are poor-
ly immunogenic due to inefficient uptake by DCs, resulting in
low levels of antigen presentation and subsequent T cell acti-
vation (1,4,7,8). A proper formulation of the SLPs with adju-
vants and a delivery vehicle is essential to compose an ade-
quate immunogenic SLP vaccine (1,4,5,7,8).
Recently, cationic liposomes have shown to be a promising
vaccine delivery platform for therapeutic cancer vaccines, as
they were able to increase the immunogenicity of antigen-
based vaccines (4,7–10). We have previously shown that cat-
ionic liposomes are suited to encapsulate several different SLP
sequences of the ovalbumin model protein and of the onco-
genic protein E7 of human papilloma virus. The liposome-
encapsulated SLPs efficiently induced functional antigen-
specific CD8+ and CD4+ T cells, and were able to induce T
cell mediated tumor regression and immunological protection
in two different tumor-bearing mouse models (4,7).
Liposomally formulated SLPs were effective at a highly re-
duced dose as compared to the SLPs emulsified in
Montanide (~65 fold lower dose), while still resulting in effi-
cient tumor killing in mice (4).
The latest advancements in cancer research have
shown the potential of a new class of highly specific tumor
antigens. These antigens arise from somatic DNA muta-
tions and result in the expression of mutated peptides on
the cancer cell surface that are not present on healthy
cells, the so-called neoepitopes (1,2,5). Multiple mutated
peptide sequences can be presented by tumor cells, which
are by definition the ideal cancer-specific vaccination tar-
gets but have originated from random DNA mutations
and are therefore patient specific. Therefore, a therapeu-
tic personalized peptide-based vaccine will contain a
unique set of mutated epitope-harboring SLPs with vari-
ous physicochemical properties (1,2,5). For that reason a
generic delivery system for neoepitope based vaccines
should be able to accommodate a wide variety of different
SLPs. The formulation strategies for such a system need
to be adjustable to variable SLP characteristics. At the
same time we aimed to limit the number of formulation
conditions to circumvent time-consuming formulation de-
velopment for every newly discovered neoepitope peptide
sequence.
In the current study we investigated the feasibility of cat-
ionic liposomes as a delivery system for SLP based cancer
vaccines. By designing 15 different model SLPs with a wide
range of physicochemical properties, in particular with respect
to isoelectric point (pI) and hydrophobicity, all harboring the
SIINFEKL epitope for immunological validation, we devel-
oped three different formulation methods to encapsulate all
these different peptides into liposomes. The physicochemical
characteristics of the liposomes were determined and in an
in vitro setting we confirmed the retained antigenic properties
of the SIINFEKL T cell epitope.
MATERIALS AND METHODS
Materials
The fluorescently labeled as well as the non-fluorescently
l abe l ed 24 -mer SLPs (Tab l e I ) i n c l ud ing the
immunodominant cytotoxic T lymphocyte epitope
[SIINFEKL] of ovalbumin were synthesized. The lipids
DOPC and DOTAP were purchased from Avanti Polar
Lipids (Alabaster, Alabama, USA). Acetonitrile (ACN),
chloroform (CHCl3), and methanol (MeOH) were obtain-
ed from Biosolve BV (Valkenswaard, the Netherlands)
and Vivaspin 2 centrifuge membrane concentrators were
purchased from Sartorius Stedim Biotech GmbH
(G ttingen, Germany). Iscove’s modified Dulbecco’s medi-
um (IMDM, Lonza Verniers, Belgium) containing 8% (v/
v) fetal calf serum (Greiner Bioscience, Alphen a/d Rijn,
the Netherlands) and 50 μM β-mercaptoethanol (Sigma-
Aldrich, Zwijndrecht, the Netherlands) was supplemented
with either 2 mM Glutamax (Thermo Fisher, Bleiswijk,
the Netherlands) and 80 IU/ml sodium-penicillin G
(Astellas, the Netherlands) for D1 cells or with 100 IU/
ml penicillin/streptomycin, 2 mM glutamin (Thermo
Fisher, Bleiswijk, the Netherlands) and 500 μg/ml
Hygromycin B (AG Scientific, San Diego, USA) for the
B3Z cells. NP-40, chlorophenol red-β-galactopyranoside
(CPRG) and dimethyl sulfoxide (DMSO) were obtained
from Sigma-Aldrich (Zwijndrecht, the Netherlands).
Deionized water with a resistivity of 18 MΩ•cm was
produced by a Millipore water purification system
(MQ water). Phosphate buffer (PB) was composed of
7.7 mM Na2HPO4
. 2 H2O and 2.3 mM NaH2PO4
. 2
H2O, (10 mM PB, pH 7.4). MQ water and 10 mM PB,
pH 7.4, were filtered through a 0.22 μm Millex GP
PES-filter (Millipore, Ireland) before use. Phosphate-
buffered saline, (PBS: 140 mM NaCl, 8.7 mM
Na2HPO4
. 12 H2O, 1.8 mM NaH2PO4
.2 H2O,
pH 7.4), which was used for the in vitro MHC class I
assays, was purchased from B.Braun (Meslungen,
Germany).
Preparation SLP Loaded Liposomes
Cationic liposomes (DOTAP:DOPC, 1:1 M ratio) contain-
ing the SLPs were produced on a small scale, 500 μl – 2 ml
per batch, by making use of the thin film dehydration-
rehydration method as previously described (4,7). For the
separate encapsulation of the SLPs a total of three different
encapsulation solvents were utilized which were dependent
on the physicochemical properties of the SLPs (Table I).
SLPs 1–6 were dissolved in ACN/H2O (1:1, v/v), SLPs 7–
10 in CHCl3:MeOH:H2O (60:36:4, v/v) and SLPs 11–15 in
0.04% NH4OH (w/v). SLPs 11 and 13 were diluted from a
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concentrated DMSO stock, while all other SLPs were dis-
solved directly from their lyophilized form. SLPs 1–6 and
11–15 were added during the rehydration of the dry lipid
film while the SLPs 7–10 were mixed with the lipid stock
solutions. After SLP loading and hydration of the dry lipid
film, the suspension was freeze dried overnight in a Christ
alpha 1–2 freeze dryer (Osterode, Germany). The following
day the lipid cake was rehydrated with PB in three consec-
utive steps: twice the addition of 25% of the final volume
(30 min equilibration after each addition) and as a third step
the remaining 50% of the final volume was added (followed
by 1 h equilibration). Down-sizing of the obtained liposomes
was done via extrusion with a Lipex extruder (Northern
Lipids Inc., Canada), the particles were extruded four times
through a 400 nm and four times through a 200 nm poly-
carbonate filter (Nucleopore Milipore, Kent, UK). After ex-
trusion the SLP-containing liposomes were separated from
the non-encapsulated SLP and concentrated by making use
of Vivaspin 2 centrifugation concentrators (molecular-
weight-cut-off of 300 kDa), as described previously (4,7).
The liposomal dispersions were concentrated 5-fold by cen-
trifugation at 931 g (2000 rpm). Subsequently, the formula-
tion was re-diluted with PB to its initial volume after which
the concentration step was repeated. During purification,
samples of the liposomal fraction and the flow-through were
taken to determine free and encapsulated peptide, as de-
scribed below.
Liposome Characterization
Physicochemical Properties and Stability of Liposomal
Formulations
The hydrodynamic diameter (Z-average) and the polydisper-
sity index (PDI) were determined by using dynamic light scat-
tering (DLS). The zeta-potential was determined by using la-
ser Doppler electrophoresis. Both measurements were per-
formed on a Zetasizer Nano (Malvern Instruments,
Malvern, UK) and prior to analysis the samples were diluted
400 fold in PB. The physicochemical properties of all liposo-
mal formulations were determined at the day of production
and after 8 weeks to determine liposome stability.
Loading Efficiency and Drug Loading of Fluorescent SLPs
The amount of liposomally encapsulated SLP in each formu-
lation was quantified via the fluorescent signal of the NBD
group (λ excitation = 462 nm, λ emission = 540 nm). In order to
calculate the loading efficiency and total drug loading of the
SLPs the liposomal samples and filtrates (containing the non-
encapsulated SLP) were collected during the purification/
concentration steps. Calibration curves were prepared for all
SLPs. In order to exclude possible interference due to the
presence of lipids a series of empty liposomes spiked calibra-
tion curves were prepared as well. All measurements were
Table I Peptides used in this Study
and their Calculated Theoretical
Isoelectric Point and Hydropathicity
Peptide ID Peptide sequence
NBD-G-XXXXXXXXXXX-SIINFEKLAAK
Theoretical pI* Hydropathicity (GRAVY)**
SLP 1 DEDKDKDDEEA 3.95 −1.208
SLP 2 DEEEKEGKEKA 4.51 −1.096
SLP 3 RKDDKDDKDLA 6.67 −0.962
SLP 4 RKHDHEHEHHA 7.93 −1.171
SLP 5 EDKKKSEKESA 9.28 −1.017
SLP 6 DEKRKKERELA 9.42 −1.004
SLP 7 DELYDLYDELA 4.13 −0.079
SLP 8 DEGLLRHLDEA 4.99 −0.163
SLP 9 DAKHDHLLHAA 7.53 −0.104
SLP 10 LDKKLLEKELA 8.61 −0.008
SLP 11 RIDIRLIIEIA 8.83 0.713
SLP 12 GSAAESASGSA 6.53 0.126
SLP 13 RDKSLKELLSA 9.54 −0.113
SLP 14 ELIDIIDIEIA 4.25 0.796
SLP 15 DLKLADLLALA 6.44 0.771
*The pI was calculated for the unlabeled peptide of which the N-terminus was not blocked, so the real theoretical pI
values are expected to be slightly lower for the labeled peptide
**The sum of hydropathy values of all amino acids, divided by the number of residues in the sequence (the NBD label
was not taken into account.). SLPs with a GRAVY score < 0 are relatively hydrophilic and SLPs with a GRAVY score > 0
are relatively hydrophobic (12,15)
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performed in 1:1 (v/v) MeOH/PB and data was acquired
with a fluorescence micro plate reader (Tecan, Salzburg,
Austria). For every formulation the loading efficiency (Eq. 1)
and peptide recovery were calculated (Eq. 2).
Loading efficiency %ð Þ




In equitation 1 the total peptide accounts for the total amount
of SLP in the liposomal dispersion prior to purification. The
free peptide is the amount non-encapsulated SLP that was de-
termined after purification.




In equitation 2 the encapsulated peptide accounts for the
amount of SLP in the purified and concentrated liposomal
dispersion. The total added peptide accounts for the amount of
SLP that was added during liposome formulation.
Liposomal Loading of Non-fluorescent SLPs
The liposomal loading of the three SLPs without fluorescent
label was determined by making use of a modified Bligh and
Dyer extraction followed by reversed-phase UPLC analysis
(see 2.3.4, below) (7). Thirty μl of liposomal formulation was
diluted in 100 μl MQ water, followed by the addition of
250 μl methanol and 150 μl chloroform. Subsequently, the
mixture was vortexed for ca. 5 s. Next, 250 μl 0.1 M HCl and
125 μl chloroform were added and the resulting mixture was
vortexed for ca. 5 s. Finally, the mixture was centrifuged at
233 g (1000 rpm) for 5 min and the upper phase was collected
for SLP quantification. The extraction efficiencies of the SLPs
were determined by spiking empty liposomes, 10 mg/ml, with
a 1 mg/ml solution of the respective SLPs.
Peptide Content
The peptide content in the upper phases of the extraction was
determined via reversed-phase UPLC (Waters Acquity
UPLC® with a waters C18–1.7 μm (2.1 × 50 mm) column).
A flow rate of 0.5 ml/min was used with initially 95% solvent
A (ACN with 0.1% TFA) and 5% solvent B (MQ with 0.1%
TFA), followed by a linear gradient to 79% solvent B in
3.97 min and back to 5% solvent A after 3.99 min.
Detection of the peptides was done by measuring the absor-
bance at a wavelength of 214 nm for 6 min. Calibration
curves, ranging from 500 μg/ml – 1.95 μg/ml, of the non-
labeled SLPs 2, 7 and 14, extracted SLPs and extraction con-
trols, 10mg/ml of empty liposomes spiked with 1mg/ml SLP,
were injected (10 μl/sample) into the UPLC system. The SLPs
were quantified by integration of the area under the curve of
the standards and extracts of the three different SLPs by using
MassLynx (Waters, software 4.1.).
In Vitro Activation of SIINFEKL Specific CD8+ T-Cells
In vitro the immunogenicity of free SLPs and liposomal SLPs
was evaluated by assessing their ability to activate immature
DCs that subsequently present the SIINFEKL epitope to
CD8+ SIINFEKL specific T cells, resulting in their activation.
In a 96-well flat-bottomed plate immature D1 (5 × 105/well)
were seeded in supplemented IMDM and incubated with ei-
ther liposomal encapsulated SLP or free SLP in an equimolar,
4-step concentration range ([C] SLP: 2 μM – 0.250 μM) for
2,5 h at 37°C and 5% CO2. After incubation the cells were
washed with supplemented IMDM to remove excess antigen
(either free or encapsulated into liposomes) and T cell hybrid-
oma B3Z cells (5 × 105/well) were added and incubated over-
night. The B3Z is a hybridoma CD8+ T cell line that is spe-
cific for the H-2 Kb-restricted SIINFEKL epitope and con-
tains the LacZ reporter under regulation of NF-AT element of
the IL-2 promoter (11). Subsequently, ligation of the T cell
receptor with the presented SIINFEKL epitope on the DC
surface results in the production of the β-galactosidase protein,
which was quantified in a colorimetric assay. After an over-
night incubation for 12 h, the cells were incubated with
chlorophenol red-β-galactopyranoside (CPRG) in a lysis buff-
er (PBS + 1% 18 mg/ml CPRG +0.9% 1 M MgCl2 +
0.125% NP40 + 0.71% 14.3 M β-mercaptoethanol) at 37°C
and 5%CO2. The SIINFEKLminimal epitope (100 ng/ml in
PBS), able to bind directly to the MHC-I complex of DCs,
served as a positive control. DC that were incubated with
empty liposomes and unstimulated DC were used as negative
controls. Cells were incubated until the color conversion was
sufficient to determine the optical density (OD) in an iMark™
mircoplate reader (Biorad, Hercules, USA) at a wavelength of
590 nm.
Peptide Characteristics Modeling
The ranges of pIs and GRAVY indices of the SLP library were
compared to those of a wide set of 24-mer peptides derived
from the human genome. To determine the pI and GRAVY
index ranges, 10 varying protein sequences were selected from
theUniprotKB database. Several commonly expressed human
household genes, tumor associated proteins and the proteins of
known neoepitopes were arbitrarily selected. All theoretically
possible 24-amino acid residue sequences for the different pro-
teins were determined by making use of a Microsoft excel
script. GRAVY index and pI for all predicted peptide
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sequences were calculated by making use of the sequence anal-
ysis tools from bioinformatics.org (12). Frequency distributions
for all GRAVY indices and pIs and their corresponding graphs
were made by using GraphPad Prism 7.
RESULTS
Peptide Characteristics & Formulation
A total of 18 different 24-mer SLPs, widely varying in hydro-
phobicity and pI, were designed so that a wide range of pI and
GRAVY indices were covered. The SLPs 1–15 consisted of a
model epitope sequence, the ovalbumin derived
SIINFEKLAAAK epitope, a variable amino acid sequence
and the NBD fluorophore, which has a relative small molec-
ular size (Mw= 165 Da) (13). The NBD fluorophore allowed
for easy quantification of the SLP in the final formulation. The
NBD group was conjugated to the peptide via an extra gly-
cine, attached to a variable amino acid sequence at the N-
terminal side of the epitope (Fig. 1). The oligo-alanine se-
quence at the C-terminus is well known to allow adequate
C-terminal proteasome cleavage of cytotoxic T cell epitopes.
Since N-terminal processing of CTL epitopes is more flexible,
it is likely that the variable sequence will allow epitope pro-
cessing and MHC-I presentation (14). For the SLPs 2, 7 and
14 the non-fluorescently labeled analogues were synthesized
as well. For all the SLP sequences the pI and hydropathicity
(GRAVY index) were calculated by making use of the se-
quence analysis tool from www.bioinformatics.org (Table I).
In order to formulate the SLPs into cationic liposomes, the
SLPs need to be fully dissolved. Because of the wide variety of
pI and GRAVY values, this turned out to be not possible with
a single solvent. Based on several exploring experiments, the
following solvents were used: ACN:H2O (1:1 v/v; solvent A),
CHCl3:MeOH:H2O (60:36:4, v/v; solvent B) and 0.04% (w/
v) NH4OH (solvent C). The SLPs 1–6 were dissolved in sol-
vent A, SLPs 7–10 in solvent B and SLPs 11–15 in solvent C.
SLPs 11 and 13 did not dissolve in 0.04% NH4OH, however,
preparing a concentrated stock solution in DMSOof the SLPs
followed by a 20-fold dilution in 0.04% NH4OH resulted in
peptide dissolution. Depending on the solvent type, the SLP
solution was added either to the lipid mixture prior to roto-
evaporation (solvent B) or to the dry lipid film during the
rehydration step (solvent A and C). In the case of the aqueous
solvents, the pH is preferably higher than the pI, to promote
electrostatic interaction between the negatively charged SLPs
and the quaternary amine group of DOTAP, which has a
permanent positive charge over the whole pH range (7,16).
Therefore, the pH of solvent A was adjusted to a value of 8.5
after peptide dissolution. In the case of solvent C, no further
pH adjustments were required, since the solvent by itself is
already basic (pH= 9.5). The SLPs that were mixed with the
lipids prior to roto-evaporation formed a homogeneous dry
lipid-peptide film. During the formulation process, the SLPs
were formulated at 1 mg/ml, except for SLP 1, which was
formulated at 0.5 mg/ml because of solubility problems at
higher concentrations.
Physicochemical Characteristics of the Liposomes
Empty liposomes and the 15 SLP loaded liposomes had com-
parable hydrodynamic diameters (Z-average < 200 nm), were
fairly monodisperse (PDI <0.22) and positively charged (zeta
potential ±26 mV) (Fig. 2). Only small differences in liposome
characteristics were observed between the different liposomal
SLP formulations, i.e., particle characteristics appeared to be
fairly independent of the loaded SLP or the used solvent.
Some of the SLP loaded liposomes had a slightly lower posi-
tive zeta potential (Fig. 2), possibly due to the characteristics of
the individual SLP. Storage of the liposomes for 8 weeks at
4°C did not detectably affect Z-average, PDI or zeta potential,
indicating that all SLPs were formulated into colloidally stable
liposomal dispersions (data not shown).
The fifteen different SLPs were all successfully loaded into
the DOTAP:DOPC liposomes (Table II). The majority of the
formulations (n= 13) were comparable regarding their encap-
sulation efficiency, indicating that the liposomes are able to
accommodate a wide range of different SLPs. In peptide re-
covery, however, more variation was observed, reflecting var-
iable losses during the production process steps, which appar-
ently depends on the physicochemical properties of the SLP.
To determine the potential influence of the fluorophore on
the liposomal characteristics, three non-fluorescently labeled
SLPs were formulated as well.
The non-labeled analogues of peptides 2, 7 and 12 were
chosen in such a way that all three different production sol-
vents were used. Encapsulation of the three SLPs yielded li-
posomes that had comparable physicochemical characteristics
(Z-average, PDI and zeta potential) to those containing the
fluorescently labeled counterparts (Z-average < 200 nm, PDI
<0.25 and zeta potential ± 26mV). However, the non-labeled
SLPs showed for all three different formulation strategies an
adequate encapsulation efficiency while a generally higher
peptide recovery was observed (Table III).
Fig. 1 Schematic representation of the fluorescent peptides used in this
study.
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In Vitro CD8+ T-Cell Activation
The immunological properties of the formulated peptides
were assessed by monitored antigen presentation by murine
DCs using the SIINFEKL specific CD8+ T cell line B3Z
in vitro. DCs are able to activate the CD8+ T cells after SLP
uptake, processing and cross-presentation of the SIINFEKL
epitope in their MHC class I molecules (11). In fig. 3 is shown
that 10 out of 15 formulations outperformed the respective
free SLPs, while 2 out of 15 SLPs showed similar levels of T
cell activation. For the remaining 5 formulations similar levels
of CD8+ T cell activation were observed for the liposomal
SLP and the free SLP. These data indicate that the used
encapsulation methods did not compromise the immunologi-
cal properties of SLPs in the final formulations. Between the
three subsets of peptides an increasing B3Z activation was
observed for SLPs with a more lipophilic character (reflected
by a high GRAVY index). Cell viability during the assay con-
ditions was controlled by presentation of the SIINFEKL min-
imal epitope and empty liposomes served as a negative control
(Supplementary Fig. 1).
Theoretical Distribution of Physicochemical Properties
of Naturally Occurring 24-Mer Peptides Derived
from the Human Genome
In order to determine the applicability of cationic lipo-
somes for encapsulation of human protein-derived SLPs
in general, the GRAVY index and pI values of the encap-
sulated SLP library were compared to those of a large set
of naturally occurring 24-mer peptide sequences. For a
Table II Loading Efficiency and
Peptide Recovery of all Liposomal



















13 0.04% NH4OH 65 7
14 9 4
15 17 5
Fig. 2 Physicochemical characteristics of empty liposomes (EL) and liposo-
mal encapsulated peptides (EP). The fifteen SLP loaded liposomal formulations
had a comparable hydrodynamic diameter, polydispersity index (a) and zeta
potential (b). Data is represented as mean ± SD (n=3).
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total of 10 different representative proteins, all theoretical
possible 24-mer long peptides (n = 5546) were determined
(alternative splicing variants were not taken into account).
Peptide sequences were determined by dissecting the pro-
tein sequence into blocks of 24 amino acids in a sequential
order (i.e., 1–24, 2–25, etc.). The included proteins were
arbitrarily selected and include human melanoma anti-
gens, neo-epitopes, and several commonly expressed hu-
man proteins to generate a wide range of different pep-
tides (Supplementary Table 1). The protein sequences
were derived from the Uniprot database and all the 24-
mer peptide sequences of each protein were listed by
making use of an excel script, after which their pI and
GRAVY index was determined. The majority of the
resulting peptide sequences (85.5%, n = 4742) fall within
the GRAVY range of our peptide library ([−1.208] –
[0.771]) whilst for the pI range this was 69.6% (n =
3860) (3.95–9.54) (Fig. 4).
DISCUSSION
In this study we investigated the potential of DOTAP-based
liposomal formulations for the loading of SLP antigens.
Cationic DOTAP:DOPC liposomes are known for their abil-
ity to enhance DC maturation, compared to negatively
charged or neutral liposomes, and are able to improve the
subsequent T cell priming when combined with an epitope-
based SLP (17,18). The production of stable liposomes is not
possible with only cationic lipids and therefore a neutral lipid,
DOPC, is included to stabilize the liposomes (19). The poten-
tial of the DOTAP:DOPC liposomes as a vaccine delivery
platform for therapeutic cancer vaccines has recently been
shown (4,7). However, the general applicability of cationic
liposomes for the encapsulation of SLPs with a large variety
of physicochemical properties has not been reported yet. This
flexibility is an essential requirement for a generic delivery
system to accommodate personalized neoepitope-based
Fig. 3 In vitro activation of the SIINFEKL-specific hybridoma CD8+ Tcells (B3Z). DCs were incubated during 2.5 h with titrated amounts [2–0.250 μM] of either
free SLP (FP) or liposomal encapsulated SLP (EP) produced with solvent A. (a), solvent B (b) or solvent C (c). The DCs were washed and co-cultured overnight
with the CD8+ Tcells. Graphs depict Tcell activation based on optical density determined (OD) at 590 nm. Data is represented as mean with range.
Table III Loading Efficiency and Peptide Recovery for Three Non-Labeled Analogues of SLPs 2, 7 and 14. The Encapsulation Efficiency and Peptide Recovery
of the Three Fluorescently Labeled SLP Analogues are Depicted in Italics Between Brackets
Peptide ID Peptide solvent Encapsulation efficiency (%) Peptide recovery (%)
2 ACN:MQ 36 (41%) 24 (9%)
7 CHCl3:MeOH:MQ 37 (51%) 60 (35%)
14 0.04% NH4OH 29 (9%) 16 (4%)
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peptide vaccines, since they will consist of a range of variable
SLPs (1,2,5). By making use of a library of fifteen SLPs, widely
varying in pI and GRAVY index values, the feasibility of our
liposomal delivery system for SLP-based vaccines was ana-
lyzed in detail.
In order to load SLPs into the cationic liposomes, we
made use of the previously optimized dehydration-
rehydration protocol for SLP encapsulation (4,7). In the cur-
rent study we applied variations to this protocol in order to
enable the encapsulation of a wide range of physicochemi-
cally distinct SLPs. A main challenge during the formulation
of some of these SLPs was to completely dissolve them prior
to their encapsulation. Previously reported data on the
DOTAP:DOPC liposomes loaded with the so-called
“OVA24” SLP, harboring the SIINFEKL epitope, showed
that a decrease of the rehydration solvents’ pH below the pI
of the SLP led to a significant reduction of the loading
efficiency (7), suggesting that the entrapment of OVA24 in
the cationic liposomes is highly dependent on electrostatic
interactions. Because of the cationic nature of the liposomes,
the SLP encapsulation might be a combination of entrap-
ment and SLP adsorption on the liposomal surface.
However, since the zeta-potentials of SLP loaded liposomes
were comparable to those of empty liposomes, we assume
that the majority of the SLPs was located inside the lipo-
somes. Although the different preparation methods for the
loading of the hydrophilic and hydrophobic SLPs might
influence the physicochemical characteristics of the particles,
we did not observe major differences between the loaded
liposomes with regard to their size, charge and polydispersi-
ty. However, for the NBD conjugated SLPs some variation
was seen regarding loading efficiency and peptide recovery.
The three non-labeled control peptides appear to perform
even better in these aspects. In the current study small batch
volumes were produced, which could have contributed to a
relatively high loss of SLPs during manufacture. This may
be overcome by the use of larger batch volumes and smaller
production equipment. This likely will reduce the relative
loss of SLP due to reduction of dead volumes and
adsorption of SLP and/or lipids to surfaces during the for-
mulation process, such as glassware and filters. The higher
peptide recoveries for the non-labeled SLPs are most likely
due to the absence of the NBD group, possibly reducing the
amount of lost SLP due to adsorption.
In an in vitro setting DCs were able to activate
SIINFEKL specific CD8+ T cells after they were incubat-
ed with the SLP loaded liposomes. These results indicate
that the encapsulation process did not hamper the immu-
nological properties of the SLPs and that the liposomes
did not interfere with the process of antigen processing
and cross-presentation by the DCs. Moreover, as com-
pared to free SLPs, liposomal delivery of SLPs seems to
promote antigen cross-presentation. The SLPs with a
GRAVY index >0 showed higher levels of CD8+ T cell
activation compared to the SLPs with lower GRAVY
values (Table I, supplementary Fig. 2). This could be
caused by differences in antigen processing due to the
different amino acid sequences or an altered mechanism
of SLP uptake by the DCs. The more hydrophobic SLPs
could potentially form additional supramolecular struc-
tures, e.g., micelles, influencing their uptake and subse-
quent processing by DCs (20,21). Therefore, when
assessing the effect of SLP encapsulation in cationic lipo-
somes, the influence of the variable sequence on the levels
of CD8+ T cell presentation was excluded by comparing
the free peptides with their liposomal equivalent for each
individual peptide. Furthermore, although we only stud-
ied the immunogenicity in vitro, in our previous work we
have shown the potential of liposomal SLPs for cancer
immunotherapy in vivo (4,7).
The data in this study show the applicability of DOTAP-
based liposomes as a flexible delivery system with intact im-
munological activity for fifteen SLPs which widely differ in
physicochemical characteristics. The comparison of charac-
teristics, GRAVY index and pI, of the used SLP library to a
wide range of human based peptides showed a large overlay,
indicating that the majority of these peptides are potential
candidates for liposomal encapsulation.
Fig. 4 Frequency distribution of 5546 possible 24-mer peptide sequences that are present in a total of 10 different arbitrarily selected human proteins. Dotted
lines represent the lower and upper limit of the (a) GRAVY index and (b) isoelectric point range of the encapsulated SLPs. For the GRAVY index 85.5% and for the
pI 69.6% of the predicted peptides are in the range of the tested SLP candidates used for liposomal encapsulation.
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CONCLUSION
In this study the separate encapsulation of an representative
array of physicochemical distinct different SLPs in
DOTAP:DOPC liposomes was described. The physicochem-
ical properties of the SLP-loaded liposomes were character-
ized and their ability to activate CD8+ T-cells after engulf-
ment and antigen presentation by dendritic cells was assessed.
The results show that the proposed formulation strategy, the
dehydration-rehydration method, in combination with three
solvent/encapsulation variants, is a feasible strategy to encap-
sulate physicochemically widely different SLPs on a small scale
with preserved immunogenicity. Hereby we underscore the
potential of DOTAP-based liposomes as a flexible particulate
delivery system for peptide based cancer vaccines. Based on
the current study and our previous work, we are now focusing
on preclinical development of DOTAP-based neoepitope
peptide vaccines.
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